Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,949 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
Lee HY, Hong JH, Byun JH, Kim HJ, Baek SK, Kim JY, Kim KH, Yun J, Kim JA, Park K, Lee HJ, Lee JL, Won YW, Kim IH, Bae WK, Park KH, Sun DS, Lee S, Lee MY, Lee GJ, Hong SH, Jung YH, An HJ. Lee HY, et al. Among authors: kim jy, kim ih, kim hj, kim ja, kim kh. Cancer Res Treat. 2020 Jan;52(1):277-283. doi: 10.4143/crt.2019.292. Epub 2019 Jul 12. Cancer Res Treat. 2020. PMID: 31319640 Free PMC article.
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Yoo C, et al. Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126. doi: 10.1177/1758835919871126. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31489036 Free PMC article.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ. Kim H, et al. Among authors: kim ih, kim dw, kim m. Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27. Cancer. 2022. PMID: 34705268 Free PMC article.
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Jung HA, Hong MH, Lee HW, Lee KH, Kim IH, Min YJ, Ahn HK, Shim BY, Choi YH, Lee YG, Kim JA, Jang JS, Shin SH, Park KU, Kang JH, Park K. Jung HA, et al. Among authors: kim ih, kim ja. Transl Lung Cancer Res. 2022 Jul;11(7):1369-1379. doi: 10.21037/tlcr-22-79. Transl Lung Cancer Res. 2022. PMID: 35958320 Free PMC article.
Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial.
Park K, Jeon YK, Kim JH, Choi Y, Kim JJ, Oh SB, Oh SY, Hong YJ, Huh SJ, Kim I, Shin SH. Park K, et al. Medicine (Baltimore). 2023 May 19;102(20):e33638. doi: 10.1097/MD.0000000000033638. Medicine (Baltimore). 2023. PMID: 37335745 Free PMC article. Clinical Trial.
1,949 results